Loading...
In 1996, Purdue Pharma launched OxyContin with a bold claim: a time-release formula that made opioid addiction 'extremely rare' — less than 1% risk. Their sales reps handed doctors a landmark 1980 letter to the editor in the New England Journal of Medicine (just five sentences long, studying hospital patients) as proof. Doctors, trusting the FDA-approved label and Purdue's army of 1,000 sales reps, prescribed OxyContin for everything from back pain to dental work. By 2001, OxyContin was a $1 billion drug. But the time-release coating could be crushed, snorted, or dissolved — delivering the full dose instantly. Patients who followed prescriptions developed physical dependence within weeks. When prescriptions ran out or doctors cut them off, patients turned to cheaper alternatives: heroin...
Popular framing: The opioid crisis was caused by a villainous pharmaceutical company that lied to doctors and got people hooked on pills, and the solution is corporate accountability and stricter prescribing rules. It wasn't just 'evil corporations'; it was a system that *demanded* a numerical fix for human suffering.
Structural analysis: The crisis was produced by a system where information asymmetry allowed manufacturers to define the evidence base, moral hazard ensured costs were externalized to patients and public payers, and reinforcing loops (dependence → supply disruption → cheaper substitutes → higher-potency substitutes) compounded each intervention's unintended consequences. The cobra effect of crackdowns without treatment expansion transformed a prescription drug problem into a fentanyl overdose crisis. The 'Principal-Agent' problem of sales reps—Purdue's reps (agents) were incentivized to increase volume, but the doctors (principals) were supposedly responsible for patient health. The incentives were perfectly misaligned.
Focusing on Purdue as the singular cause satisfies the narrative need for a villain but leaves the underlying incentive architecture intact — other manufacturers, the same regulatory framework, and the same fee-for-service prescribing model remain. Without addressing the structural feedback loops, the system will produce analogous crises through different molecules or markets.
